Anemia of Chronic Kidney Disease Clinical Trial
Official title:
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) ("Extension Period").
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) ("Extension Period"). The study will consist of 14 clinic visits over a period of 24 weeks. There will be a screening period of up to 14 days; Approximately 230 subjects will be randomized into the Randomized Period in a 1:1 ratio to receive either KRX-0502 or matching placebo, at baseline ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03325621 -
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02198495 -
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
|
Phase 4 | |
| Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
| Completed |
NCT02581124 -
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
Phase 1 | |
| Completed |
NCT04543812 -
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
|
Phase 3 | |
| Recruiting |
NCT05900635 -
Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients
|
Phase 4 | |
| Completed |
NCT04667533 -
Desidustat in the Treatment of Chemotherapy Induced Anemia
|
Phase 1 | |
| Completed |
NCT03731741 -
Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
|
Phase 2 | |
| Completed |
NCT02787824 -
Periodic Versus Continuous IV Iron Supplementation in HD Patients
|
Phase 4 | |
| Completed |
NCT03431623 -
CKD-11101 Phase 3 SC Study
|
Phase 3 | |
| Completed |
NCT01971164 -
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
|
Phase 1 | |
| Recruiting |
NCT01532349 -
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT05698420 -
Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
|
||
| Completed |
NCT03427801 -
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
|
||
| Recruiting |
NCT03521713 -
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
|
Phase 3 | |
| Active, not recruiting |
NCT02754167 -
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02805244 -
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
|
Phase 1 | |
| Completed |
NCT03428594 -
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
|
Phase 3 | |
| Not yet recruiting |
NCT06352138 -
Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients
|
Phase 3 | |
| Suspended |
NCT05082584 -
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
|
Phase 3 |